Binding pharmaceuticals to ion exchange resins
Patent 5413782 Issued on May 9, 1995. Estimated Expiration Date: 
November 10, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
November 10, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2990332 3109775 3143465 3499960 3594470 New oral form of medicament and a method for producing it Prolonged release pharmaceutical preparations Theophylline sustained release granule Sustained absorption pharmaceutical composition Sustained release drug-resin complexes InventorsAssigneeApplicationNo. 974099 filed on 11/10/1992US Classes:424/78.15, Plural nitrogen heteroatoms or rings424/78.1Ion exchange resinExaminersPrimary: Page, Thurman K.Assistant: Kulkosky, Peter F. Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/74A61K 009/14 AbstractIn a method in which an ionizable pharmaceutical material, such as theophylline, having a pharmaceutically-active anionic group is bonded to an anion exchange resin having cationic groups bonded to displacable anionic groups by bringing said material and said resin into contact with each other under conditions such that the pharmaceutically-active anionic group of said material is bonded to the cationic group of said resin and replaces the anionic group thereof, the improvement comprising effecting said contact in an environment which is substantially free of carbon dioxide and/or bicarbonate ion, a pharmacologically active composition comprising said pharmaceutically active anion and said resin, including a composition in which at least about 40% of the binding capacity of the resin comprises said pharmaceutically active anion, and a sustained release pharmaceutical composition, including enteric coated particles of the composition, and stabilizing said composition by maintaining it in an environment substantially free of bicarbonate and/or carbon dioxide.Other References
| |
